Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Want to see ARCT full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized meaningful clinical and regulatory progress — notably initiation of a 12‑week ARCT‑032 Phase II with tolerable repeat inhaled dosing and FDA clarity on ARCT‑810 pediatric path — supported by a strengthened leadership team and a cash runway through mid‑2028. Offsetting these positives were a material year‑over‑year revenue decline ($27.3M), a quarter‑over‑quarter cash decrease (~$19.4M, 8.3%), program‑specific manufacturing cost increases, and uncertainties tied to a small open‑label CF study and broader modality risk. On balance, the advancement of key programs and regulatory alignment outweigh the financial and operational headwinds in the near term.Company Guidance
ARCT-032 (Inhaled mRNA CF) Advancement to 12‑Week Phase II
Initiated enrollment in a 12-week open-label Phase II in Q1 2026; study already >1 month of dosing and moving beyond the 28‑day exposures seen previously. Cohort 4 permits 10 mg (initiated) or 15 mg daily dosing; protocol set for up to ~20 subjects with expanded sites outside the U.S. Endpoints include percent predicted FEV1, lung clearance index (LCI), HRCT imaging and QoL measures.
Tolerability Milestone for Repeat Dosing in CF
Reported tolerable continuous inhaled dosing beyond one month — a first for inhaled mRNA therapeutics — enabled by proprietary LUNAR particle chemistry and a unique mRNA purification process; no steroid co‑treatment and approved unsupervised at‑home dosing are highlighted differentiators.
Regulatory Clarity for ARCT-810 (OTC Deficiency)
Completed Type C meeting(s) with FDA and received clear regulatory direction toward a pediatric pivotal development path; company collecting additional exploratory data (including 0.3 and 0.5 dose groups) and planning an end‑of‑Phase II meeting in H2 2026 to align on pediatric strategy.
Preclinical & Translational Support for CF Program
Preclinical data show LNP stability in sputum and delivery to bronchial epithelial cells in mouse, ferret and nonhuman primate models; nebulizer particle size optimized for lung distribution; prior cohort HRCT showed mucus‑plug reductions that may correlate with lung function improvements.
Commercial Partner Progress — KOSTAIVE Manufacturing
Meiji (Japan) actively manufacturing KOSTAIVE (self‑amplifying mRNA COVID vaccine) in a 2‑dose vial presentation for the 2026–2027 season; commercial guidance for Japan to be provided by Meiji.
Strengthened Executive Team
Appointed Dennis Mulroy as CFO and Dr. Alan Cohen as CMO, expanding leadership with clinical, regulatory and financial expertise.
Cash Position and Runway
Cash, cash equivalents and restricted cash of $213.4 million as of March 31, 2026 and management states a cash runway extending beyond Q2 2028 to support near‑term milestones.
ARCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $8.90 | $9.22 | +3.60% |
Mar 03, 2026 | $7.91 | $7.58 | -4.17% |
Nov 10, 2025 | $8.78 | $8.67 | -1.25% |
Aug 11, 2025 | $11.39 | $14.89 | +30.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arcturus Therapeutics (ARCT) report earnings?
Arcturus Therapeutics (ARCT) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Arcturus Therapeutics (ARCT) earnings time?
Arcturus Therapeutics (ARCT) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARCT EPS forecast?
ARCT EPS forecast for the fiscal quarter 2026 (Q2) is -1.
